Immunohistochemically Detectable Bcl-2 Expression in Metastatic Melanoma: Association with Survival and Treatment Response

Publisher： Karger

E-ISSN： 1423-0232|62|3|259-268

ISSN： 0030-2414

Source： Oncology, Vol.62, Iss.3, 2002-06, pp. : 259-268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib

By  

Oncology Research and Treatment, Vol. 40, Iss. 4, 2017-03 ,pp. : 174-183

Karger

Access to resources Recommend Favorite

Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient

By  

Case Reports in Oncology, Vol. 6, Iss. 2, 2013-05 ,pp. : 285-288

Karger

Access to resources Recommend Favorite

Treatment for metastatic melanoma: a new and evolving era

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 3, 2015-03 ,pp. : 273-280

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-12 ,pp. : 123-126

Karger

Access to resources Recommend Favorite

Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 403-409

Karger

Access to resources Recommend Favorite